JP2016518337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518337A5 JP2016518337A5 JP2016503044A JP2016503044A JP2016518337A5 JP 2016518337 A5 JP2016518337 A5 JP 2016518337A5 JP 2016503044 A JP2016503044 A JP 2016503044A JP 2016503044 A JP2016503044 A JP 2016503044A JP 2016518337 A5 JP2016518337 A5 JP 2016518337A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- selective cdk4
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 16
- 239000011780 sodium chloride Substances 0.000 claims 16
- 102100019398 CDK4 Human genes 0.000 claims 14
- 101700008359 CDK4 Proteins 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 14
- 230000002401 inhibitory effect Effects 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000000389 T-Cell Leukemia Diseases 0.000 claims 6
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- YPJRHEKCFKOVRT-UHFFFAOYSA-N CC(C)N(CC1)CCN1c(cc1)cnc1Nc1ncc(cc2[n]3C4(CCCCC4)CNC2=O)c3n1 Chemical compound CC(C)N(CC1)CCN1c(cc1)cnc1Nc1ncc(cc2[n]3C4(CCCCC4)CNC2=O)c3n1 YPJRHEKCFKOVRT-UHFFFAOYSA-N 0.000 description 1
Claims (26)
- 前記T細胞白血病が、急性リンパ芽球性白血病である、請求項15に記載の使用。
- 前記T細胞白血病が、慢性リンパ性白血病である、請求項15に記載の使用。
- 対象がヒトである、請求項15に記載の使用。
- 対象がヒトである、請求項16に記載の使用。
- 対象がヒトである、請求項17に記載の使用。
- 前記T細胞白血病が、急性リンパ芽球性白血病である、請求項21に記載の使用。
- 前記T細胞白血病が、慢性リンパ性白血病である、請求項21に記載の使用。
- 対象がヒトである、請求項21に記載の使用。
- 対象がヒトである、請求項22に記載の使用。
- 対象がヒトである、請求項23に記載の使用。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361798772P | 2013-03-15 | 2013-03-15 | |
US61/798,772 | 2013-03-15 | ||
US201361861374P | 2013-08-01 | 2013-08-01 | |
US61/861,374 | 2013-08-01 | ||
US201361911354P | 2013-12-03 | 2013-12-03 | |
US61/911,354 | 2013-12-03 | ||
US201461949795P | 2014-03-07 | 2014-03-07 | |
US61/949,795 | 2014-03-07 | ||
PCT/US2014/029274 WO2014144740A2 (en) | 2013-03-15 | 2014-03-14 | Highly active anti-neoplastic and anti-proliferative agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018202981A Division JP6703583B2 (ja) | 2013-03-15 | 2018-10-29 | 高活性抗新生物薬及び抗増殖剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016518337A JP2016518337A (ja) | 2016-06-23 |
JP2016518337A5 true JP2016518337A5 (ja) | 2017-04-20 |
JP6435315B2 JP6435315B2 (ja) | 2018-12-05 |
Family
ID=51527866
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016503044A Active JP6435315B2 (ja) | 2013-03-15 | 2014-03-14 | 高活性抗新生物薬及び抗増殖剤 |
JP2018202981A Active JP6703583B2 (ja) | 2013-03-15 | 2018-10-29 | 高活性抗新生物薬及び抗増殖剤 |
JP2020082401A Pending JP2020128408A (ja) | 2013-03-15 | 2020-05-08 | 高活性抗新生物薬及び抗増殖剤 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018202981A Active JP6703583B2 (ja) | 2013-03-15 | 2018-10-29 | 高活性抗新生物薬及び抗増殖剤 |
JP2020082401A Pending JP2020128408A (ja) | 2013-03-15 | 2020-05-08 | 高活性抗新生物薬及び抗増殖剤 |
Country Status (7)
Country | Link |
---|---|
US (6) | US20140271460A1 (ja) |
EP (1) | EP2967050A4 (ja) |
JP (3) | JP6435315B2 (ja) |
CN (2) | CN107417691B (ja) |
CA (2) | CA3152117A1 (ja) |
HK (1) | HK1222766A1 (ja) |
WO (1) | WO2014144740A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
CN108283644B (zh) | 2013-03-15 | 2022-03-18 | G1治疗公司 | 在化学疗法期间对正常细胞的瞬时保护 |
WO2015161287A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of normal cells during chemotherapy |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
KR102445288B1 (ko) | 2016-07-01 | 2022-09-19 | 쥐원 쎄라퓨틱스, 인크. | N-(헤테로아릴)-피롤로[3,2-d]피리미딘-2-아민의 합성 |
EP3858835A1 (en) | 2016-07-01 | 2021-08-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
EP3548030A4 (en) | 2016-12-05 | 2020-08-12 | G1 Therapeutics, Inc. | PRESERVATION OF THE IMMUNE RESPONSE IN CHEMOTHERAPIES |
CN110177554B (zh) * | 2017-01-06 | 2023-06-02 | G1治疗公司 | 用于治疗癌症的组合疗法 |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
CA3067873A1 (en) * | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of g1t38 and methods of manufacture thereof |
WO2019133864A1 (en) * | 2017-12-29 | 2019-07-04 | Accutar Biotechnology | DUAL INHIBITORS OF PARP1 and CDK |
WO2019136451A1 (en) * | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
JP2023508357A (ja) | 2019-12-23 | 2023-03-02 | アキュター バイオテクノロジー インコーポレイテッド | エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ |
MX2022014573A (es) | 2020-05-19 | 2022-12-15 | G1 Therapeutics Inc | Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos. |
IL298568A (en) * | 2020-06-11 | 2023-01-01 | Lunella Biotech Inc | Selective cancer drugs cdk4/6 inhibitors |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591855A (en) | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
AU778735B2 (en) | 1998-06-16 | 2004-12-16 | Centre National De La Recherche Scientifique | Fused azepinone cyclin dependent kinase inhibitors |
ATE380548T1 (de) | 1999-01-29 | 2007-12-15 | Univ Illinois | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie |
DE60024631T2 (de) | 1999-07-26 | 2006-06-14 | Banyu Pharma Co Ltd | Biaryl-harnstoff-derivate |
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
US6291504B1 (en) | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
EP1242420A2 (en) | 1999-12-16 | 2002-09-25 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
DK1294724T3 (da) | 2000-06-26 | 2006-07-17 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidinforbindelser som immunosuppresive midler |
WO2002028861A2 (en) | 2000-09-29 | 2002-04-11 | Eli Lilly And Company | Methods and compounds for treating proliferative diseases |
AU2002228692A1 (en) | 2000-12-01 | 2002-06-11 | Bristol-Myers Squibb Pharma Company | 3-(2,4-dimethylthiazol-5-yl) indeno(1,2-c)pyrazol-4-one derivatives as cdk inhibitors |
US6667346B2 (en) | 2001-02-28 | 2003-12-23 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones |
CN100341572C (zh) * | 2001-05-11 | 2007-10-10 | 得克萨斯州立大学董事会 | 抗cd26单克隆抗体作为对与表达cd26的细胞相关疾病的治疗 |
CN101001857B (zh) | 2002-01-22 | 2011-06-22 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
WO2003093469A2 (en) | 2002-05-01 | 2003-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
DE602004021558D1 (de) | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
OA13170A (en) | 2003-05-22 | 2006-12-13 | Pharmacia Italia Spa | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. |
CN1835951B (zh) | 2003-07-11 | 2010-06-02 | 沃尼尔·朗伯有限责任公司 | 选择性cdk4抑制剂的羟乙基磺酸盐 |
DE602004010419T2 (de) | 2003-10-23 | 2008-10-09 | F. Hoffmann-La Roche Ag | Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen |
GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
JP2007530654A (ja) | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
WO2005100999A2 (en) | 2004-04-08 | 2005-10-27 | Cornell Research Foundation, Inc. | Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer |
ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
AU2006205851A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
KR20070107707A (ko) | 2005-01-21 | 2007-11-07 | 아스텍스 테라퓨틱스 리미티드 | 피라졸 키나제 억제제와 추가 항종양제의 조합물 |
AU2006251623A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
WO2007065820A1 (en) | 2005-12-09 | 2007-06-14 | F. Hoffmann-La Roche Ag | Tricyclic amide derivatives useful for treating obesity |
CA2631777A1 (en) | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
JP2009532503A (ja) | 2006-04-05 | 2009-09-10 | ノバルティス アクチエンゲゼルシャフト | 癌を処置するための治療剤の組合せ |
US20070270362A1 (en) | 2006-05-18 | 2007-11-22 | The University Of Washington | Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders |
AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
AU2007333791A1 (en) | 2006-12-14 | 2008-06-26 | Panacea Pharmaceuticals, Inc. | Methods of neuroprotection by cyclin-dependent kinase inhibition |
US20100048597A1 (en) | 2006-12-22 | 2010-02-25 | Novartis Ag | Organic Compounds and Their Uses |
CN101784541A (zh) | 2007-06-25 | 2010-07-21 | 纽罗根公司 | 哌嗪基氧代烷基四氢-β-咔啉及相关类似物 |
US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
KR20100095020A (ko) | 2007-12-19 | 2010-08-27 | 암젠 인크 | 세포 주기 억제제로서의 융합된 피리딘, 피리미딘 및 트리아진 화합물 |
ES2964764T3 (es) | 2008-07-29 | 2024-04-09 | Nerviano Medical Sciences Srl | Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino |
CN102186856B (zh) * | 2008-08-22 | 2014-09-24 | 诺华股份有限公司 | 作为cdk抑制剂的吡咯并嘧啶化合物 |
WO2010039997A2 (en) | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
US20110224221A1 (en) | 2008-10-01 | 2011-09-15 | Sharpless Norman E | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
JP2012526850A (ja) | 2009-05-13 | 2012-11-01 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | サイクリン依存性キナーゼ阻害剤及びその用法 |
WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
DK2632467T3 (en) | 2010-10-25 | 2016-08-15 | G1 Therapeutics Inc | CDK inhibitors |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
PL2635583T3 (pl) | 2010-11-02 | 2015-11-30 | Promega Corp | Pochodne koelenterazyny i metody ich wykorzystania |
EP2640394A4 (en) | 2010-11-17 | 2015-02-25 | Univ North Carolina | PROTECTION OF RENAL TISSUES AGAINST ISCHEMIA THROUGH INHIBITION OF CDK4 AND CDK6 PROLIFERATIVE KINASES |
PL2655375T3 (pl) | 2010-12-23 | 2015-05-29 | Sanofi Sa | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie |
PT2688887E (pt) * | 2011-03-23 | 2015-07-06 | Amgen Inc | Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3 |
PE20141381A1 (es) | 2011-07-01 | 2014-10-21 | Novartis Ag | Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer |
CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
MY175254A (en) | 2012-04-26 | 2020-06-17 | G1 Therapeutics Inc | Synthesis of lactams |
US9241941B2 (en) | 2012-09-20 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Methods for treatment of lymphomas with mutations in cell cycle genes |
US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
CN108283644B (zh) | 2013-03-15 | 2022-03-18 | G1治疗公司 | 在化学疗法期间对正常细胞的瞬时保护 |
EP2983670A4 (en) | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
WO2015084892A1 (en) | 2013-12-02 | 2015-06-11 | Cornell University | Methods for treating b cell proliferative disorders |
WO2015161287A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of normal cells during chemotherapy |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
-
2014
- 2014-03-14 JP JP2016503044A patent/JP6435315B2/ja active Active
- 2014-03-14 CA CA3152117A patent/CA3152117A1/en active Pending
- 2014-03-14 EP EP14764016.3A patent/EP2967050A4/en active Pending
- 2014-03-14 CN CN201710147181.4A patent/CN107417691B/zh active Active
- 2014-03-14 WO PCT/US2014/029274 patent/WO2014144740A2/en active Application Filing
- 2014-03-14 US US14/213,784 patent/US20140271460A1/en not_active Abandoned
- 2014-03-14 CN CN201480027263.XA patent/CN105407723A/zh active Pending
- 2014-03-14 CA CA2906157A patent/CA2906157C/en active Active
-
2016
- 2016-07-01 US US15/201,286 patent/US20160310499A1/en not_active Abandoned
- 2016-09-18 HK HK16110954.5A patent/HK1222766A1/zh unknown
-
2017
- 2017-09-22 US US15/713,385 patent/US20180015096A1/en not_active Abandoned
-
2018
- 2018-10-29 JP JP2018202981A patent/JP6703583B2/ja active Active
- 2018-12-20 US US16/228,308 patent/US10709711B2/en active Active
-
2020
- 2020-05-08 JP JP2020082401A patent/JP2020128408A/ja active Pending
- 2020-07-10 US US16/926,035 patent/US20200345743A1/en not_active Abandoned
-
2022
- 2022-08-17 US US17/890,130 patent/US20230248733A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016518337A5 (ja) | ||
JP2017509667A5 (ja) | ||
JP2013014622A5 (ja) | ||
JP2017186358A5 (ja) | ||
JP2014507446A5 (ja) | ||
JP2016515522A5 (ja) | ||
JP2014221779A5 (ja) | ||
JP2017537066A5 (ja) | ||
JP2015078230A5 (ja) | ||
JP2013525444A5 (ja) | ||
JP2016508134A5 (ja) | ||
JP2015503422A5 (ja) | ||
JP2017514871A5 (ja) | ||
CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
JP2014530840A5 (ja) | ||
EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
JP2017537912A5 (ja) | ||
JP2015516419A5 (ja) | ||
WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
JP2016532632A5 (ja) | ||
WO2015179823A8 (en) | Lung localized inhibitors of alpha(v)beta 6 | |
JP2014148552A5 (ja) | ||
LT3124048T (lt) | Kompozicija skirta vartoti per burną gastroezofaginio refliukso ligos ar skausmo gydymui | |
WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat |